Therapeutic interventions for prevention of recurrent ischemic stroke

American Journal of Managed Care

Volumn 14, Issue SUPPL. 7, 2008, Pages

  Kirshner, Howard S ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b SelectHealth   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; GEMFIBROZIL; GLUCOSE; LIPID; NICOTINIC ACID; PLACEBO; PRASUGREL; PRAVASTATIN; SIMVASTATIN; TICLOPIDINE; WARFARIN;

ALCOHOL CONSUMPTION; BLEEDING; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; NEUTROPENIA; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SMOKING; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION;

EVIDENCE-BASED MEDICINE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; RECURRENCE; RISK FACTORS; RISK REDUCTION BEHAVIOR; STROKE;

EID: 46149123240     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/ American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of the guidelines. Stroke. 2006;37(2): 577-617.
2. American Heart Association/American Stroke Association. Heart Disease and Stroke Statistics, 2008 Update At-a-Glance. http://www. americanheart.org/ downloadable/heart/1200082005246HS_Stats%202008. final.pdf. Accessed March 27, 2008.
3. Alberts MJ, Atkinson R. Risk reduction strategies in ischaemic stroke: the role of antiplatelet therapy. Clin Drug Investig. 2004;24(5):245-254.
4. Diener HC. Update on clopidogrel and dual antiplatelet therapy: neurology. Eur Heart J. 2006;8(suppl G):G15-G19.
5. Liao JK. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Circulation. 2007;115(12):1615-1621.
6. Jamieson DG, Parekh A, Ezekowitz MD. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. J Cardiovasc Pharmacol Ther. 2005;10(3):153-161.
7. Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke. 2000;31(9):2080-2086.
8. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year survival after first-ever stroke in the Perth Community Stroke Study. Stroke. 2003;34(8): 1842-1846.
9. Hartmann A, Rundek T, Mast H, et al. Mortality and causes of death after first ischemic stroke: the Northern Manhattan Stroke Study. Neurology. 2001;57(11): 2000-2005.
10. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24(6):796-800.
11. Amarenco P, Bogousslavsky J, Callahan A 3rd; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
12. Adams RJ, Albers G, Alberts MJ, et al; American Heart Association, American Stroke Association. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008;39(5):1647-1652.
13. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiology. 1998;81(3):333-335.
14. Wiviott SD, Braunwald E, McCabe CH, et al, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med. 2007;357(20):2001-2015.
15. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH Jr, Folsom AR. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities Study. Stroke. 2006;37(10):2493-2498.
16. Schulz UG, Rothwell PM. Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke. 2003;34(8):2050-2059.
17. Murat Sumer M, Erturk O. Ischemic stroke subtypes: risk factors, functional outcome and recurrence. Neurol Sci. 2002;22(6):449-454.
18. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41.
19. Jackson C, Sudlow C. Are lacunar strokes really different? A systematic review of differences in risk factor profiles between lacunar and nonlacunar infarcts. Stroke. 2005;36(4):891-901.
20. Laloux P, Galanti L, Jamart J. Lipids in ischemic stroke subtypes. Acta Neurol Belg. 2004;104(1):13-19.
21. Song YM, Kwon SU, Sung J, et al. Different risk factor profiles between subtypes of ischemic stroke. A case-control study in Korean men. Eur J Epidemiol. 2005; 20(7):605-612.
22. Suk SH, Sacco RL, Boden-Albala B, et al; Northern Manhattan Stroke Study. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2003;34(7):1586-1592.
23. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology. 2004;63(10):1868-1875.
24. Vibo R, Korv J, Roose M, et al. Acute phase proteins and oxidised low-density lipoprotein in association with ischemic stroke subtype, severity and outcome. Free Radic Res. 2007;41(3):282-287.
25. Paganini-Hill A, Lozano E, Fischberg G, et al. Infection and risk of ischemic stroke: differences among stroke subtypes. Stroke. 2003;34(2):452-457.
26. Grau AJ, Buggle F, Lichy C, Brandt T, Becher H, Rudi J. Helicobacter pylori infection as an independent risk factor for cerebral ischemia of atherothrombotic origin. J Neurol Sci. 2001;186(1-2):1-5.
27. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocysteine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke. 2000;31(5):1069-1075.
28. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke. 2000;31(5):1062-1068.
29. Shin DH, Lee PH, Bang OY. Mechanisms of recurrence in subtypes of ischemic stroke: a hospital-based follow-up study. Arch Neurol. 2005;62(8):1232-1237.
30. Yusuf S, Teo KK, Pogue J, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358:1547-1559.
31. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19): 1349-1357.
32. Plehn JF, Davis BR, Sacks FM, et al; The CARE Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin. Circulation. 1999;99(2):216-223.
33. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002;106(13): 1690-1695.
34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360(9326): 7-22.
35. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363(9411):757-767.
36. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449-1457.
37. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in BMJ. 2002(7330);324:14]. BMJ. 2002(7329); 324:71-86.
38. PRoFESS results announced at XVII European Stroke Conference. PharmaLive.com, May 14, 2008. http://www.engelpub.com/News/index.cfm?articleid= 540393. Accessed May 16, 2008.
39. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038): 1329-1339.
40. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry. 1996;60(2):197-199.
41. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry. 1999;66(2):255.
42. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1-2):1-13.
43. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A; ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial [published correction appears in Lancet. 2007;369(9558):274]. Lancet. 2006;367(9523):1665-1673.
44. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54(12):1044-1054.
45. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325(18):1261-1266.
46. Mohr JP, Sciacca RR, Thompson JLP, et al. Aspirin failure in the warfarin aspirin recurrent stroke study. Program and abstracts of the 28th International Stroke Conference; February 13-15, 2003; Phoenix, Arizona. Abstract 100698.
47. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Foxx KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
48. Sabatine MS, Cannon CP, Gibson CM, et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12): 1179-1189.
49. Chen ZM, Jiang LX, Chen YP, et al; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005; 366(9497):1607-1621.
50. Diener HC, Bogousslavsky J, Brass LM, et al; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331-337.
51. Bhatt DL, Fox KA, Hacke W, et al; CHARISMA investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
52. Bhatt DL, Flather MD, Hacke W, et al; CHARISMA investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19): 1982-1988.
53. Hart RG, Bhatt DL, Hacke W, et al; CHARISMA investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis. 2008;25(4): 344-347.